Recent Posts

• Aulos Bioscience Presents Poster on Phase 1/2 Clinical Trial of Computationally Designed IL-2 Antibody AU-007 at 2022 ASCO Annual Meeting May 26, 2022
• Aulos Bioscience Initiates Phase 1/2 Clinical Trial of IL-2 Therapeutic AU-007 for the Treatment of Solid Tumors May 5, 2022
• Aulos Bioscience Announces Presentation on First-in-Human Phase 1/2 Clinical Trial of Novel IL-2 Therapeutic AU-007 at 2022 ASCO Annual Meeting April 27, 2022
• Aulos Bioscience Announces Preclinical Data Demonstrating Ability of Novel IL-2 Therapeutic AU-007 to Eliminate Solid Tumors March 21, 2022
• Aulos Bioscience Receives HREC Approval to Initiate First-in-Human Clinical Trial Evaluating Anti-Tumor Activity of Novel IL-2 Therapeutic AU-007 February 23, 2022
• Aulos Bioscience Presents Preclinical Data Demonstrating Anti-Tumor Activity of AU-007, a Novel IL-2 Therapeutic, at 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting November 12, 2021
• Aulos Bioscience to Present New Preclinical Data on Computationally Evolved IL-2 Human Antibody AU-007 at 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting October 5, 2021
• Jim Vasselli, M.D., Joins Aulos Bioscience as Chief Medical Officer June 14, 2021
• Aulos Bioscience Appoints Leo Redmond as Chief Financial Officer May 17, 2021
• Mace Rothenberg, M.D., Joins Aulos Bioscience Board of Directors March 30, 2021
• Aulos Bioscience Appoints Aron Knickerbocker as CEO March 15, 2021
• ATP and Biolojic Design Launch Aulos Bioscience to Develop Highly Differentiated IL-2 Antibody Approach to Fighting Cancer January 8, 2021